Question normal

Greetings from Ecuador. It is well recognized that there is a residual risk even when we effectively treat patients with statins and that risk can be measured or evaluated with non-HDL colesterol which is a better predictor of CV events. My question is why did you use LDLc to show the benefit instead of Non-HDL? Thanks and congratulations for the study. I think is a really well designed and conducted trial.